Search for: "EMD Serono, Inc." Results 1 - 19 of 19
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 May 2011, 4:46 am by Dan Hargrove
Pharmaceutical manufacturers Serono Laboratories, Inc., EMD Serono, Inc., Merck Serono S.A., and Ares Trading S.A., have agreed to pay $44.3 million to resolve False Claims Act allegations in connection with the marketing of the drug Rebif. [read post]
5 May 2011, 2:57 pm by LaBovick Law
Pharmaceutical giants: Serono Laboratories Inc., EMD Serono Inc., Merck Serono S.A, and Ares Trading S.A. have agreed to settle False Claims Act allegations in connection with the marketing of the drug Rebif for $44.3 million, according to a recent announcement by the Department of Justice. [read post]
4 May 2011, 6:14 am by Ben Vernia
According to DOJ’s press release: P harmaceutical manufacturers Serono Laboratories Inc., EMD Serono Inc., Merck Serono S.A, and Ares Trading S.A. have agreed to pay $44.3 million to resolve False Claims Act allegations in connection with the marketing of the drug Rebif, the Justice Department announced. [read post]
30 Sep 2020, 5:47 am by Richard Marsolais
EMD Serono, Inc, the US Court of Appeals for the Federal Circuit (“Federal Circuit”) reversed a district court’s grant of judgment as a matter of law of no anticipation, reinstating a jury verdict. [read post]
19 Feb 2009, 2:46 pm
  At the recommendation of Health Canada, EMD Serono Canada Inc. has  suspended the marketing of Raptiva in Canada due to safety concerns, including  the increased risk of developing PML. [read post]
31 Mar 2016, 3:00 am
EMD Serono, Inc., No. 5:14-cv-01709-MHH, 2016 WL 1086028 (Mar. 21, N.D. [read post]
6 Oct 2020, 7:55 am by Courtenay C. Brinckerhoff
EMD Serono, Inc., and includes an interesting discussion of claim construction for method claims reciting product-by-process limitations. [read post]
20 Sep 2021, 3:31 pm by Dennis Crouch
EMD Serono, Inc., the Federal Circuit found the claimed treatment method anticipated by use of a naturally occurring protein. [read post]
13 Jun 2012, 6:22 pm by Stephen Jenei
Mark Halligan, Partner, Nixon Peabody LLP and Thomas Kelley, Consulting Patent Counsel, Monsanto Company Speaker: Jason Duncan, Associate General Counsel, EMD, Serono, Inc. [read post]